Military gets new PTSD treatment option—but evidence is still emerging
H.R. 8764 — TREAT PTSD TRICARE Act · Filed by Scott Perry (R-PA) · Introduced May 12, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Department of Defense to offer stellate ganglion block (SGB)—a nerve-blocking injection used experimentally to treat PTSD symptoms—to all active-duty and reserve service members diagnosed with PTSD who enroll in TRICARE and consent to the procedure. The DoD must update its clinical practice guidelines within 180 days to include SGB as a therapy option and inform Congress of the update.
Why we flagged it
The bill's operative mechanism is a straightforward expansion of TRICARE benefits to include a specific emerging therapy for a defined population (PTSD-diagnosed service members). It is a healthcare access measure, not a deregulation, subsidy carve-out, or commemorative act.
What the text implies
- SGB is an emerging/experimental therapy with mixed clinical evidence; widespread DoD adoption may accelerate its use before long-term safety/efficacy data are mature, potentially exposing service members to off-label risks.
- The bill does not specify funding source or appropriation; implementation cost and budget impact on TRICARE are not addressed, creating potential fiscal uncertainty.
- Guideline update requirement may influence VA policy as well (VA/DOD joint guideline), potentially expanding SGB access beyond DoD to VA beneficiaries without explicit legislative authorization.
- No requirement for outcome tracking, adverse-event reporting, or comparative effectiveness data; DoD may lack systematic data on SGB outcomes in its population.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Service members with PTSD gain access to an emerging therapeutic option at no personal cost, with informed consent protections and clinical guideline oversight. The bill expands treatment choice without restricting existing options or imposing costs on the public.
Who stands to gain
- healthcare providers administering SGB procedures
- medical device/pharmaceutical suppliers of SGB materials
Named in the bill
Department of Defense, TRICARE, VA/DOD Clinical Practice Guideline, Congressional Defense Committees, Armed Forces (active duty and reserve components)
Where it stands
- May 12, 2026 — Introduced · Congress.gov: “Introduced in House”
- May 12, 2026 — Referred to House Committee on Armed Services · Congress.gov: “Referred to the House Committee on Armed Services”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (2,389 characters) on Aug 24, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Military gets new PTSD treatment option—but evidence is still emerging” QuorumCivic. https://share.quorumcivic.app/bill/119/hr8764 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.